0001209191-22-009565.txt : 20220214 0001209191-22-009565.hdr.sgml : 20220214 20220214195800 ACCESSION NUMBER: 0001209191-22-009565 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220210 FILED AS OF DATE: 20220214 DATE AS OF CHANGE: 20220214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BJERKHOLT ERIC CENTRAL INDEX KEY: 0001197350 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37345 FILM NUMBER: 22636490 MAIL ADDRESS: STREET 1: 132 PURDURE AVENUE CITY: KENGSINGTON STATE: CA ZIP: 94708 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CHINOOK THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001435049 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 FAIRVIEW AVENUE NORTH, SUITE 900 CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 206-485-7051 MAIL ADDRESS: STREET 1: 400 FAIRVIEW AVENUE NORTH, SUITE 900 CITY: SEATTLE STATE: WA ZIP: 98109 FORMER COMPANY: FORMER CONFORMED NAME: ADURO BIOTECH, INC. DATE OF NAME CHANGE: 20111107 FORMER COMPANY: FORMER CONFORMED NAME: ADURO BIOTECH DATE OF NAME CHANGE: 20080514 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-02-10 0 0001435049 CHINOOK THERAPEUTICS, INC. KDNY 0001197350 BJERKHOLT ERIC C/O CHINOOK THERAPEUTICS, INC. 400 FAIRVIEW AVE. NO., 9TH FLOOR SEATTLE WA 98102 0 1 0 0 Chief Financial Officer Common Stock 2022-02-10 4 M 0 2434 A 23098 D Common Stock 2022-02-11 4 S 0 895 12.7412 D 22203 D Restricted Stock Units (RSU) 2022-02-10 4 M 0 2434 0.00 D 2024-02-10 Common Stock 2434 4870 D Restricted stock units convert into common stock on a one-for-one basis. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.64 to $12.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 10, 2022, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. /s/ Kirk Schumacher, Attorney-in-Fact 2022-02-14